

# Brian G Weinshenker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/386035/publications.pdf>

Version: 2024-02-01

226  
papers

49,592  
citations

6233

80  
h-index

1705

213  
g-index

230  
all docs

230  
docs citations

230  
times ranked

23227  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
2	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
3	Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". <i>Annals of Neurology</i> , 2005, 58, 840-846.	2.8	4,495
4	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. <i>Neurology</i> , 2015, 85, 177-189.	1.5	3,275
5	Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2000, 343, 938-952.	13.9	3,121
6	A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. <i>Lancet</i> , The, 2004, 364, 2106-2112.	6.3	2,839
7	The spectrum of neuromyelitis optica. <i>Lancet Neurology</i> , The, 2007, 6, 805-815.	4.9	1,897
8	A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. <i>Brain</i> , 2002, 125, 1450-1461.	3.7	1,078
9	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. <i>Annals of Neurology</i> , 1999, 46, 878-886.	2.8	832
10	Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. <i>Scientific Reports</i> , 2016, 6, 28484.	1.6	660
11	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. <i>Brain</i> , 2007, 130, 1194-1205.	3.7	650
12	Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression. <i>Archives of Neurology</i> , 2006, 63, 964.	4.9	643
13	Brain Abnormalities in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2006, 63, 390.	4.9	637
14	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. <i>Annals of Neurology</i> , 2006, 59, 566-569.	2.8	548
15	Neuromyelitis Optica and Non-Organ-Specific Autoimmunity. <i>Archives of Neurology</i> , 2008, 65, 78-83.	4.9	497
16	Treatment of Neuromyelitis Optica With Rituximab. <i>Archives of Neurology</i> , 2008, 65, 1443.	4.9	445
17	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet</i> , The, 2019, 394, 1352-1363.	6.3	433
18	Interferon beta-1b in secondary progressive MS. <i>Neurology</i> , 2004, 63, 1788-1795.	1.5	413

#	ARTICLE	IF	CITATIONS
19	Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. <i>Lancet, The</i> , 2005, 366, 579-582.	6.3	411
20	Glial fibrillary acidic protein immunoglobulin <scp>G</scp> as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. <i>Annals of Neurology</i> , 2017, 81, 298-309.	2.8	366
21	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. <i>Lancet Neurology, The</i> , 2013, 12, 554-562.	4.9	335
22	Natural history of multiple sclerosis. <i>Annals of Neurology</i> , 1994, 36, S6-S11.	2.8	323
23	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). <i>Brain</i> , 2010, 133, 2626-2634.	3.7	316
24	Neuromyelitis optica. <i>Neurology</i> , 2003, 60, 848-853.	1.5	308
25	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019, 142, 1858-1875.	3.7	303
26	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. <i>American Journal of Ophthalmology</i> , 2018, 195, 8-15.	1.7	295
27	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgGâ€“Associated Disorders. <i>JAMA Neurology</i> , 2018, 75, 1355.	4.5	286
28	Treatment of Neuromyelitis Optica With Mycophenolate Mofetil. <i>Archives of Neurology</i> , 2009, 66, 1128-33.	4.9	283
29	Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. <i>Lancet Neurology, The</i> , 2020, 19, 402-412.	4.9	278
30	Epidemiology of aquaporinâ€“4 autoimmunity and neuromyelitis optica spectrum. <i>Annals of Neurology</i> , 2016, 79, 775-783.	2.8	263
31	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology, The</i> , 2021, 20, 762-772.	4.9	261
32	The investigation of acute optic neuritis: a review and proposed protocol. <i>Nature Reviews Neurology</i> , 2014, 10, 447-458.	4.9	248
33	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301.	4.5	243
34	Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85.	18.1	232
35	The contemporary spectrum of multiple sclerosis misdiagnosis. <i>Neurology</i> , 2016, 87, 1393-1399.	1.5	230
36	Neuromyelitis Spectrum Disorders. <i>Mayo Clinic Proceedings</i> , 2017, 92, 663-679.	1.4	224

#	ARTICLE	IF	CITATIONS
37	Treatment of neuromyelitis optica: Review and recommendations. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 180-187.	0.9	217
38	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. <i>Frontiers in Neurology</i> , 2020, 11, 501.	1.1	216
39	An Approach to the Diagnosis of Acute Transverse Myelitis. <i>Seminars in Neurology</i> , 2008, 28, 105-120.	0.5	210
40	Short Myelitis Lesions in Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorders. <i>JAMA Neurology</i> , 2015, 72, 81.	4.5	209
41	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. <i>Neurology</i> , 2013, 81, 1197-1204.	1.5	206
42	Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 188-198.	1.4	205
43	A point mutation in PTPRC is associated with the development of multiple sclerosis. <i>Nature Genetics</i> , 2000, 26, 495-499.	9.4	197
44	Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. <i>Annals of Neurology</i> , 2004, 56, 303-306.	2.8	197
45	The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. <i>Multiple Sclerosis Journal</i> , 2012, 18, 5-10.	1.4	192
46	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. <i>Archives of Neurology</i> , 2011, 68, 870.	4.9	173
47	Intractable vomiting as the initial presentation of neuromyelitis optica. <i>Annals of Neurology</i> , 2010, 68, 757-761.	2.8	168
48	Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. <i>Brain</i> , 2010, 133, 333-348.	3.7	164
49	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <i>Annals of Neurology</i> , 2016, 79, 437-447.	2.8	148
50	Acute Disseminated Encephalomyelitis: Current Understanding and Controversies. <i>Seminars in Neurology</i> , 2008, 28, 084-094.	0.5	143
51	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020, 95, e111-e120.	1.5	140
52	Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. <i>JAMA Neurology</i> , 2019, 76, 56.	4.5	134
53	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019, 142, 1310-1323.	3.7	131
54	Neuromyelitis optica. <i>Current Treatment Options in Neurology</i> , 2008, 10, 55-66.	0.7	129

#	ARTICLE	IF	CITATIONS
55	Area postrema syndrome. <i>Neurology</i> , 2018, 91, e1642-e1651.	1.5	129
56	Disease modifying therapies for relapsing multiple sclerosis. <i>BMJ, The</i> , 2016, 354, i3518.	3.0	127
57	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. <i>JAMA Neurology</i> , 2021, 78, 741.	4.5	124
58	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. <i>Muscle and Nerve</i> , 2009, 39, 87-90.	1.0	123
59	Atypical inflammatory demyelinating syndromes of the CNS. <i>Lancet Neurology, The</i> , 2016, 15, 967-981.	4.9	121
60	Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	112
61	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology, The</i> , 2019, 18, 185-197.	4.9	110
62	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251.	0.9	110
63	Natural history of multiple sclerosis. <i>Neurologic Clinics</i> , 2005, 23, 17-38.	0.8	108
64	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. <i>Ophthalmology</i> , 2018, 125, 1628-1637.	2.5	108
65	Evaluation of aquaporin-4 antibody assays. <i>Clinical and Experimental Neuroimmunology</i> , 2014, 5, 290-303.	0.5	106
66	Neuromyelitis optica: Changing concepts. <i>Journal of Neuroimmunology</i> , 2007, 187, 126-138.	1.1	104
67	Update on biomarkers in neuromyelitis optica. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e134.	3.1	104
68	The Natural History of Recurrent Optic Neuritis. <i>Archives of Neurology</i> , 2004, 61, 1401.	4.9	100
69	Radiologically Isolated Syndrome: <math>10\text{-Year}</math> Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020, 88, 407-417.	2.8	95
70	Central canal enhancement and the trident sign in spinal cord sarcoidosis. <i>Neurology</i> , 2016, 87, 743-744.	1.5	94
71	Relapses and disability accumulation in progressive multiple sclerosis. <i>Neurology</i> , 2015, 84, 81-88.	1.5	92
72	Effects of Age and Sex on Aquaporin-4 Autoimmunity. <i>Archives of Neurology</i> , 2012, 69, 1039-43.	4.9	91

#	ARTICLE	IF	CITATIONS
73	Neuromyelitis optica. Current Treatment Options in Neurology, 2005, 7, 173-182.	0.7	90
74	Specific pattern of gadolinium enhancement in spondylotic myelopathy. Annals of Neurology, 2014, 76, 54-65.	2.8	89
75	Diagnosis of Neuromyelitis Spectrum Disorders. Archives of Neurology, 2009, 66, 1134-8.	4.9	87
76	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology, 2015, 85, 722-729.	1.5	86
77	Neuromyelitis optica. Current Opinion in Neurology, 2007, 20, 255-260.	1.8	85
78	The Natural History of Multiple Sclerosis: Update 1998. Seminars in Neurology, 1998, 18, 301-307.	0.5	84
79	Neuromyelitis optica: what it is and what it might be. Lancet, The, 2003, 361, 889-890.	6.3	82
80	NMO-IgG: A Specific Biomarker for Neuromyelitis Optica. Disease Markers, 2006, 22, 197-206.	0.6	82
81	Neuromyelitis Optica Is Distinct From Multiple Sclerosis. Archives of Neurology, 2007, 64, 899.	4.9	82
82	Screening for Major Depression in the Early Stages of Multiple Sclerosis. Canadian Journal of Neurological Sciences, 1995, 22, 228-231.	0.3	79
83	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. JAMA Neurology, 2020, 77, 937.	4.5	78
84	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.5	77
85	Misdiagnosis of Multiple Sclerosis: Frequency, Causes, Effects, and Prevention. Current Neurology and Neuroscience Reports, 2013, 13, 403.	2.0	76
86	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	2.8	72
87	OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurology, The, 2006, 5, 110-111.	4.9	71
88	Aquaporin 4 Expression and Tissue Susceptibility to Neuromyelitis Optica. JAMA Neurology, 2013, 70, 1118.	4.5	70
89	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2016, 86, 491-492.	1.5	68
90	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	1.4	64

#	ARTICLE	IF	CITATIONS
91	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	1.4	63
92	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	1.8	60
93	Cerebrospinal Fluid Oligoclonal Bands in the Diagnosis of Multiple Sclerosis. American Journal of Clinical Pathology, 2003, 120, 672-675.	0.4	59
94	Progressive solitary sclerosis. Neurology, 2016, 87, 1713-1719.	1.5	59
95	High risk of postpartum relapses in neuromyelitis optica spectrum disorder. Neurology, 2017, 89, 2238-2244.	1.5	59
96	Cervical spinal cord atrophy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e435.	3.1	57
97	Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials. Nature Reviews Neurology, 2021, 17, 759-773.	4.9	57
98	Longitudinally extensive transverse myelitis. Current Opinion in Neurology, 2014, 27, 279-289.	1.8	56
99	Elsberg syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e355.	3.1	55
100	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e343.	3.1	55
101	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 384-390.	0.9	55
102	Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis. Archives of Neurology, 2006, 63, 611.	4.9	54
103	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 488-490.	0.9	54
104	Neuromyelitis optica (Devic's syndrome). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 581-599.	1.0	53
105	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 218-225.	0.9	53
106	Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2014, 71, 48.	4.5	51
107	Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel. Clinical Gastroenterology and Hepatology, 2013, 11, 240-245.	2.4	49
108	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. Neurology, 2015, 84, 148-158.	1.5	49

#	ARTICLE	IF	CITATIONS
109	Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 331-339.	1.4	45
110	Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. <i>Journal of Clinical Apheresis</i> , 2001, 16, 39-42.	0.7	44
111	Solitary sclerosis: Progressive myelopathy from solitary demyelinating lesion. <i>Neurology</i> , 2012, 78, 540-544.	1.5	44
112	Approach to acute or subacute myelopathy. <i>Neurology</i> , 2010, 75, S2-8.	1.5	43
113	Neuromyelitis Optica Spectrum Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 483.	2.0	42
114	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. , 1999, 14, 144-148.		39
115	Multiple sclerosis, brain radiotherapy, and risk of neurotoxicity: The Mayo Clinic experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 1178-1186.	0.4	39
116	Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815.	1.5	39
117	Familial chordoma with probable autosomal dominant inheritance. , 1998, 75, 335-336.		37
118	Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. <i>Journal of Clinical Apheresis</i> , 1995, 10, 163-170.	0.7	36
119	Optic Disc Edema in Glial Fibrillary Acidic Protein Autoantibodyâ€“Positive Meningoencephalitis. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 276-281.	0.4	36
120	Failure of Autologous Hematopoietic Stem Cell Transplantation to Prevent Relapse of Neuromyelitis Optica. <i>Archives of Neurology</i> , 2011, 68, 953.	4.9	35
121	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1808-1817.	1.4	35
122	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101487.	0.9	35
123	Interferon Gamma Allelic Variants. <i>Archives of Neurology</i> , 2008, 65, 349-57.	4.9	33
124	Compressive Myelopathy Mimicking Transverse Myelitis. <i>Neurologist</i> , 2010, 16, 120-122.	0.4	32
125	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e339.	3.1	32
126	Challenges in multiple sclerosis diagnosis: Misunderstanding and misapplication of the McDonald criteria. <i>Multiple Sclerosis Journal</i> , 2021, 27, 250-258.	1.4	32



#	ARTICLE	IF	CITATIONS
127	Optic neuritis in an ethnically diverse population: Higher risk of atypical cases in patients of African or African-Caribbean heritage. <i>Journal of the Neurological Sciences</i> , 2012, 312, 21-25.	0.3	31
128	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG-associated disorders (MOGAD)? <i>Neurology</i> , 2020, 94, 85-88.	1.5	30
129	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. <i>JAMA Neurology</i> , 2021, 78, 351.	4.5	30
130	Neuromyelitis Optica IgG Serostatus in Fulminant Central Nervous System Inflammatory Demyelinating Disease. <i>Archives of Neurology</i> , 2009, 66, 964-6.	4.9	29
131	A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 57.	2.0	29
132	MOG-IgG1 and co-existence of neuronal autoantibodies. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1175-1186.	1.4	29
133	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	29
134	Corticosteroid-Induced Paraplegia—A Diagnostic Clue for Spinal Dural Arterial Venous Fistula. <i>JAMA Neurology</i> , 2015, 72, 833.	4.5	28
135	Spinal cord infarction: Clinical and imaging insights from the periprocedural setting. <i>Journal of the Neurological Sciences</i> , 2018, 388, 162-167.	0.3	28
136	Reproductive history and progressive multiple sclerosis risk in women. <i>Brain Communications</i> , 2020, 2, fcaa185.	1.5	28
137	Acute Disseminated Encephalomyelitis, Transverse Myelitis, and Neuromyelitis Optica. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2013, 19, 944-967.	0.4	27
138	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019, 93, e414-e420.	1.5	26
139	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 630-635.	1.4	25
140	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021, 97, e1351-e1358.	1.5	25
141	Hydrocephalus in neuromyelitis optica. <i>Neurology</i> , 2014, 82, 1841-1843.	1.5	22
142	Unilateral motor progression in MS. <i>Neurology</i> , 2019, 93, e628-e634.	1.5	22
143	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. <i>Neurology</i> , 2007, 68, 1326-1327.	1.5	21
144	The two faces of neuromyelitis optica. <i>Neurology</i> , 2014, 82, 466-467.	1.5	21

#	ARTICLE	IF	CITATIONS
145	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. <i>Neurology: Clinical Practice</i> , 2015, 5, 175-177.	0.8	21
146	Utility of MRI Enhancement Pattern in Myelopathies With Longitudinally Extensive T2 Lesions. <i>Neurology: Clinical Practice</i> , 2021, 11, e601-e611.	0.8	21
147	ACUTE LEUKOENCEPHALOPATHIES. <i>Neurologist</i> , 1998, 4, 148-166.	0.4	20
148	Pregnancy outcomes in a woman with neuromyelitis optica. <i>Neurology</i> , 2014, 83, 1576-1577.	1.5	20
149	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	20
150	HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2010, 16, 981-984.	1.4	19
151	Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1445-1452.	1.4	18
152	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. <i>JAMA Neurology</i> , 2018, 75, 892.	4.5	17
153	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. <i>Mayo Clinic Proceedings</i> , 2022, 97, 738-751.	1.4	17
154	BalÃ³ concentric sclerosis evolving from apparent tumefactive demyelination. <i>Neurology</i> , 2017, 88, 2150-2152.	1.5	16
155	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	0.9	16
156	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	1.4	16
157	Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. <i>Neurology</i> , 2018, 90, 1106-1112.	1.5	15
158	Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAKuraSky and SAKuraStar. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 66, 104025.	0.9	15
159	Western vs optic-spinal MS: Two diseases, one treatment?. <i>Neurology</i> , 2005, 64, 594-595.	1.5	14
160	Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101413.	0.9	14
161	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. <i>JAMA Neurology</i> , 2020, 77, 1572.	4.5	14
162	Acute Demyelinating Disorders: Emergencies and Management. <i>Neurologic Clinics</i> , 2012, 30, 285-307.	0.8	12

#	ARTICLE	IF	CITATIONS
163	Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. <i>Multiple Sclerosis Journal</i> , 2017, 23, 182-184.	1.4	12
164	Multiple sclerosis diagnosis: Knowledge gaps and opportunities for educational intervention in neurologists in the United States. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1248-1256.	1.4	12
165	Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD. <i>Neurology</i> , 2022, 99, .	1.5	12
166	Teaching Neuro <i>Images</i> : "Pancake-like" gadolinium enhancement suggests compressive myelopathy due to spondylosis. <i>Neurology</i> , 2013, 80, e229.	1.5	11
167	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	1.4	11
168	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110526.	0.5	11
169	Gait Apraxia in Multiple Sclerosis. <i>Canadian Journal of Neurological Sciences</i> , 2009, 36, 562-565.	0.3	10
170	ASYMPTOMATIC SPINAL CORD INVOLVEMENT IN POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME. <i>Neurology</i> , 2010, 74, 1478-1479.	1.5	10
171	Optimizing rituximab therapy for neuromyelitis optica. <i>Nature Reviews Neurology</i> , 2011, 7, 664-665.	4.9	10
172	Simultaneous PML-IRIS and myelitis in a patient with neuromyelitis optica spectrum disorder. <i>Neurology: Clinical Practice</i> , 2013, 3, 448-451.	0.8	10
173	Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1746-1747.	1.4	10
174	Anterior spinal artery infarction causing man-in-the-barrel syndrome. <i>Neurology: Clinical Practice</i> , 2014, 4, 268-269.	0.8	9
175	Disease-modifying therapies can be safely discontinued in an individual with stable relapsing-remitting MS "NO. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1190-1192.	1.4	9
176	Association of <i>IL2RA</i> polymorphisms with susceptibility to multiple sclerosis is not explained by missense mutations in <i>IL2RA</i> . <i>Multiple Sclerosis Journal</i> , 2011, 17, 634-636.	1.4	8
177	Pediatric familial neuromyelitis optica in two sisters with long term follow-up. <i>Journal of Clinical Neuroscience</i> , 2016, 29, 183-184.	0.8	8
178	Pregnancy. <i>Neurology</i> , 2012, 78, 846-848.	1.5	7
179	Active and progressive. <i>Neurology</i> , 2014, 83, 206-207.	1.5	7
180	What is the optimal sequence of retreatments for attacks of neuromyelitis optica spectrum disorder?. <i>Annals of Neurology</i> , 2016, 79, 204-205.	2.8	7

#	ARTICLE	IF	CITATIONS
181	McArdle Sign: A Specific Sign of Multiple Sclerosis. Mayo Clinic Proceedings, 2019, 94, 1427-1435.	1.4	7
182	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	1.4	7
183	Laquinimod, a new oral drug for multiple sclerosis. Lancet, The, 2008, 371, 2059-2060.	6.3	6
184	Teaching Neuro <i>Images</i> : MRI in advanced neuromyelitis optica. Neurology, 2014, 82, e101-2.	1.5	6
185	Myelitis in neuromyelitis optica spectrum disorder: The long and the short of it. Multiple Sclerosis Journal, 2017, 23, 360-361.	1.4	6
186	Population-based study of "no evident disease activity" in MS. Neurology: Neuroimmunology and Neuroinflammation, 2018, 5, e495.	3.1	6
187	More on Multiple Sclerosis and Neuromyelitis Optica"Reply. Archives of Neurology, 2007, 64, 1802.	4.9	5
188	Japanese optic-spinal MS. Neurology, 2010, 75, 1404-1405.	1.5	5
189	Lupus Related Longitudinal Myelitis. Journal of Rheumatology, 2011, 38, 1520-1520.	1.0	5
190	Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?. Neurology, 2011, 77, 812-813.	1.5	5
191	Clinical Significance of Myelin Oligodendrocyte Glycoprotein Autoantibodies in Patients with Typical MS Lesions on MRI. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021, 7, 205521732110487.	0.5	5
192	Neuromyelitis Optica and Autoimmune Diseases"Reply. Archives of Neurology, 2008, 65, 992.	4.9	4
193	Neuromyelitis Optica. Blue Books of Neurology, 2010, 35, 258-275.	0.1	4
194	Relapsing inappropriate antidiuretic hormone secretion in an anti-aquaporin-4 antibody positive paediatric patient. Multiple Sclerosis Journal, 2014, 20, 1404-1406.	1.4	4
195	Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 709-714.	1.4	4
196	Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 895-902.	1.4	4
197	Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology: Clinical Practice, 2022, 12, 263-269.	0.8	4
198	Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder". Neurology and Therapy, 2022, 11, 1439-1443.	1.4	4

#	ARTICLE	IF	CITATIONS
199	Placebo Studies should not be Undertaken in Neuromyelitis Optica: Commentary. Multiple Sclerosis Journal, 2015, 21, 693-694.	1.4	3
200	Inflammatory activity following motor progression due to critical CNS demyelinating lesions. Multiple Sclerosis Journal, 2021, 27, 1037-1045.	1.4	3
201	Clinical spectrum of neuromyelitis optica 2013. Neurology and Clinical Neuroscience, 2014, 2, 23-27.	0.2	2
202	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. Multiple Sclerosis and Related Disorders, 2019, 35, 34-35.	0.9	2
203	Biomechanical muscle stiffness measures of extensor digitorum explain potential mechanism of McArdle sign. Clinical Biomechanics, 2021, 82, 105277.	0.5	2
204	A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. , 1999, 46, 878.		2
205	Neuromotor control associates with muscle weakness observed with <scp>McArdle</scp> sign of multiple sclerosis. Annals of Clinical and Translational Neurology, 2022, , .	1.7	2
206	Letter to the editor. Clinical Therapeutics, 2003, 25, 1888-1890.	1.1	1
207	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: No. Multiple Sclerosis Journal, 2012, 18, 1211-1212.	1.4	1
208	Plasmapheresis: are bigger studies necessarily better?. Nature Reviews Neurology, 2012, 8, 410-410.	4.9	1
209	Christian Confavreux (1949 – 2013). Multiple Sclerosis Journal, 2013, 19, 1811-1812.	1.4	1
210	Review: In relapsing&#x2014;remitting multiple sclerosis, disease-modifying agents reduce annual relapse rates. Annals of Internal Medicine, 2014, 160, JC5.	2.0	1
211	Moving Targets for Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2015, 72, 147.	4.5	1
212	Teaching Neuro <i>Images</i> : Primary Sj&#x0000;gren syndrome presenting as isolated lesion of medulla oblongata. Neurology, 2015, 85, 204-205.	1.5	1
213	Efficacy and Safety of Satralizumab for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder: A Pooled Analysis from Two Phase 3 Clinical Trials. Multiple Sclerosis and Related Disorders, 2020, 37, 101592.	0.9	1
214	Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. , 1999, 14, 144.		1
215	&#x201c;A rose by any other name&#x201c; does defining extreme phenotypes add to the management of multiple sclerosis?. Annals of Translational Medicine, 2018, 6, 396-396.	0.7	1
216	Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110521.	0.5	1

#	ARTICLE	IF	CITATIONS
217	Do old HLA and mitochondrial DNA variants associate with demyelination types in young patients?. Neurology, 2011, 76, 768-769.	1.5	0
218	Spinal Cord Compression and Myelopathies. , 2012, , 235-257.		0
219	<i>TNFRSF1A</i> polymorphisms and MS. Neurology, 2013, 80, 2002-2003.	1.5	0
220	Posterior reversible encephalopathy syndrome is not associated with mutations in aquaporin-4: Table. Neurology: Genetics, 2015, 1, e19.	0.9	0
221	EXPERT OPINIONS ON THE DIAGNOSIS AND TREATMENT OF PATIENTS WITH AQP4-NEGATIVE NMO/MS OVERLAPPING SYNDROMES. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.40-e4.	0.9	0
222	Does early (treatment in) BENEFIT lead to late MS benefit?. Neurology, 2016, 87, 970-971.	1.5	0
223	Variation in MS outcome. Neurology, 2017, 88, 1214-1215.	1.5	0
224	Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology, 2017, 88, 2067-2068.	1.5	0
225	Spinal Cord Compression and Myelopathies. , 2021, , 251-278.		0
226	Vessel Wall Enhancement in Unilateral Primary Angiitis of the Central Nervous System. Canadian Journal of Neurological Sciences, 2021, , 1-3.	0.3	0